Novo Nordisk Earnings Could Be Solid, but Consensus Still Too High -- Market Talk

Dow Jones

03/30

0958 GMT - Novo Nordisk's first-quarter results could be solid, with a strong beat for the Wegovy treatment in oral form and a 2026 guidance reiteration, J.P. Morgan analysts write in a research note. "Overall, we anticipate a solid set of results, slightly ahead of consensus on adjusted operating profit and adjusted EPS." However, the bank still thinks that consensus is significantly too high, particularly at the operating profit level. JPM says that a 5% cut to consensus is required just to get to the top-end of the Danish drugmaker's guidance range, so even with a strong oral Wegovy result it sees the potential for consensus numbers to come down following the results. Shares rise 0.6% to 229.80 Danish kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

March 30, 2026 05:59 ET (09:59 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2623151263"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2623151263\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2623151263?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 17:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623151263","market":"hk","top_or_hot":-1,"title":"Novo Nordisk Earnings Could Be Solid, but Consensus Still Too High -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0958 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s first-quarter results could be solid, with a strong beat for the Wegovy treatment in oral form and a 2026 guidance reiteration, J.P. Morgan analysts write in a research note. \"Overall, we anticipate a solid set of results, slightly ahead of consensus on adjusted operating profit and adjusted EPS.\" However, the bank still thinks that consensus is significantly too high, particularly at the operating profit level. <a href=\"https://laohu8.com/S/JPM\">JPM</a> says that a 5% cut to consensus is required just to get to the top-end of the Danish drugmaker's guidance range, so even with a strong oral Wegovy result it sees the potential for consensus numbers to come down following the results. Shares rise 0.6% to 229.80 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 30, 2026 05:59 ET (09:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Earnings Could Be Solid, but Consensus Still Too High -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Earnings Could Be Solid, but Consensus Still Too High -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-30 17:59</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0958 GMT - <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s first-quarter results could be solid, with a strong beat for the Wegovy treatment in oral form and a 2026 guidance reiteration, J.P. Morgan analysts write in a research note. \"Overall, we anticipate a solid set of results, slightly ahead of consensus on adjusted operating profit and adjusted EPS.\" However, the bank still thinks that consensus is significantly too high, particularly at the operating profit level. <a href=\"https://laohu8.com/S/JPM\">JPM</a> says that a 5% cut to consensus is required just to get to the top-end of the Danish drugmaker's guidance range, so even with a strong oral Wegovy result it sees the potential for consensus numbers to come down following the results. Shares rise 0.6% to 229.80 Danish kroner. (dominic.chopping@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 30, 2026 05:59 ET (09:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVOX","symbol_name":"2倍做多NVO ETF-Defiance","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2623151263","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623151263","pubTimestamp":1774864740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0958 GMT - Novo Nordisk's first-quarter results could be solid, with a strong beat for the Wegovy treatment in oral form and a 2026 guidance reiteration, J.P. Morgan analysts write in a research note. \"Overall, we anticipate a solid set of results, slightly ahead of consensus on adjusted operating profit and adjusted EPS.\" However, the bank still thinks that consensus is significantly too high, particularly at the operating profit level. JPM says that a 5% cut to consensus is required just to get to the top-end of the Danish drugmaker's guidance range, so even with a strong oral Wegovy result it sees the potential for consensus numbers to come down following the results. Shares rise 0.6% to 229.80 Danish kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVOX":"2倍做多NVO ETF-Defiance","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","NVO":"诺和诺德","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4599":"减肥药","BK4007":"制药","NVOH":"Novo Nordisk A/S B Shares ADRhedged","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4588":"碎股"},"translate_title":"诺和诺德盈利可能稳健，但共识仍然过高——市场传言","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOH":0.6,"NVOX":0.6,"NVO":1.95},"content_text":"0958 GMT - Novo Nordisk's first-quarter results could be solid, with a strong beat for the Wegovy treatment in oral form and a 2026 guidance reiteration, J.P. Morgan analysts write in a research note. \"Overall, we anticipate a solid set of results, slightly ahead of consensus on adjusted operating profit and adjusted EPS.\" However, the bank still thinks that consensus is significantly too high, particularly at the operating profit level. JPM says that a 5% cut to consensus is required just to get to the top-end of the Danish drugmaker's guidance range, so even with a strong oral Wegovy result it sees the potential for consensus numbers to come down following the results. Shares rise 0.6% to 229.80 Danish kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 05:59 ET (09:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}